1/46
Looks like no tags are added yet.
Define cytotoxic anticancer treatments
Treatments that target rapidly dividing cells
Define biologic anticancer treatments
Treatments that target intracellular signaling
Define immunotherapies as anticancer treatment
Treatments that modulate the immune system
Define a grade 1 adverse event
MILD
Asymptomatic or mild symptoms
Clinical or diagnostic observations only
Intervention not indicated
Define a grade 2 adverse event
MODERATE
Minimal, local or noninvasive intervention indicated
Limiting age appropriate instrumental ADL
Define a grade 3 adverse event
Severe or medically significant but not immediately life-threatening
Hospitalization or prolongation of hospitalization indicated
Disabling = limiting self care ADL
Define a grade 4 adverse event
Life-threatening consequences
Urgent intervention indicated
Define a grade 5 adverse event
Death related to AE
What is used to reduce the incidence of febrile neutropenia (FN)?
Myeloid growth factors (MGF's)
Define febrile neutropenia (FN)
Single temperature ≥ 38.3ºC orally or 38.0ºC over 1 h
AND
Neutropenia of < 500 cells/mm^3 or < 1000 cells/mm^3 and a predicted decline to ≤ 500 cells/mm^3 over the next 48 hours
What are used to manage chemotherapy-induced anemia?
Erythropoiesis-stimulating agents (ESAs)
What are risks associated with neutropenia?
Increased risk of infection
Inability of body to amount an immune response to pathogen
Describe the relationship between neutrophil count and mortality from uncontrolled infection
INVERSE RELATIONSHIP
Nadir neutrophil count > 1000/mm^3 = little risk of infection
Nadir neutrophil count < 500/mm^3 = risk of death is markedly increased
What is the normal half-life of a neutrophil cell?
6-12 hours
What are notable examples of medications used to treat neutropenia?
Filgrastim
Pegfilgrastim
What reduces the duration and severity of neutropenia?
The use of G-CSFs with antimicrobials
When is G-CSF primary prophylaxis given for neutropenia?
Given AUTOMATICALLY with cycle 1
When is G-CSF secondary prophylaxis given for neutropenia?
Given AFTER a patient started
Why might a patient be given secondary prophylaxis for neutropenia?
Patient experiences FN
Prolonged recovery of counts (prolonged neutropenic event)
If either of these, ADD filgrastim or pegfilgrastim
Define curative intent
The medical goal of curing a disease or condition
Define palliative intent
A medical care approach that focuses on relieving symptoms and improving the quality of life for patients with serious or life-threatening illnesses, rather than curing the disease itself
Define a high risk regimen for FN
Regimens where clinical trials show an incidence of FN ≥ 20%
Define an intermediate risk regimen for FN
Regimens which show an incidence of FN between 10-20%
When is FN prophylaxis automatically given?
If the patient is CURATIVE intent AND the regimen is HIGH risk
Give either filgrastim or pegfilgrastim
When should patient risk factors be assessed for FN primary prophylaxis?
If regimen has an intermediate risk for FN
When should G-CSF primary prophylaxis be considered for a patient on an intermediate risk regimen?
Prior chemotherapy or radiation therapy
Persistent neutropenia
Bone marrow involvement by tumor
Recent surgery and/or open wounds
Hepatic dysfunction (bilirubin > 2.0)
Renal dysfunction (CrCl < 50)
Age > 65 years receiving full chemotherapy dose intensity
Which medication is a short-acting G-CSF?
Filgrastim (and biosimilars)
What is the daily dose of filgrastim?
5 mcg/kg/daily SQ
Round to the nearest full vial size = 300 mcg or 480 mcg
When should filgrastim be started?
The next day or up to 3 days after completion of myelosuppressive chemotherapy and treat through post-nadir recovery
How long should filgrastim be continued?
Up to 14 days or until nadir has passed
When should filgrastim be discontinued?
If ANC > 10,000/mm^3 after expected chemotherapy-induced nadir occurs
What is the MOA of filgrastim?
Stimulates the production, maturation, and activation of neutrophils to increase both their migration and cytotoxicity
What medication is a long-acting G-CSF?
Pegfilgrastim (and biosimilars)
What is the dose of pegfilgrastim and when should it be administered?
6 mg SQ
Administered 1 day after myelosuppressive chemotherapy (up to 72 hours after is acceptable)
How many days should there be between the dose of pegfilgrastim and the next cycle of chemotherapy?
At least 12 days
What makes pegfilgrastim a long acting CSF?
Created by adding a polyethylene glycol molecule to G-CSF
What is the notable toxicity of myeloid growth factors?
Bone pain
What are baseline investigations for anemia in patients with cancer receiving chemotherapy?
Drug exposure history
Review of peripheral blood smear
Analysis of iron, TIBC, transferrin sat., ferritin, folate, B12
Assessment of reticulocyte found, occult blood loss and renal insufficiency
BASELINE ERYTHROPOIETIN LEVEL
What are treatment options for anemia as a result of chemotherapy?
Packed red blood cell transfusion
Erythropoiesis-stimulating agent (ESAs)
Iron replacement
When is a packed red blood cell transfusion given?
Progressive decline in hemoglobin due to chemotherapy (< 8)
Dyspnea, tachycardia, chest pain, syncope
What are examples of ESAs?
Epoetin alfa
Darbepoetin
What is the MOA of epoetin alfa?
Induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells
Induces the release of reticulocytes from the bone marrow into the blood stream, where they mature to erythrocytes
What is the onset of epoetin alfa?
Within 10 days
What is a notable difference between epoetin alfa and darbepoetin?
Darbepoetin has an increased half-life compared to epoetin alfa
SQ half-life is longer than IV half-life for both drugs
What is the onset of darbepoetin?
Typically 2-6 weeks
What are risks associated with the use of ESA in cancer?
Increased thrombotic events
Possible decreased survival
What are the goals of the use of ESA in cancer?
Transfusion avoidance
Gradual improvement in anemia related symptoms